T Cell News and Research

Latest T Cell News and Research

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012

AICAR therapy may combat heat stroke

We've all seen the story in the news before. Whether it's the death of a physically fit high school athlete at football training camp in August, or of an elderly woman gardening in the middle of the day in July, heat stroke is a serious, life-threatening condition for which there is no treatment beyond submersion in ice water or the application of ice packs to cool the body to a normal temperature.

8 Jan 2012

Scientists develop simple, reliable test to identify biomarkers for MPS

A team of scientists, led by researchers at the University of California, San Diego School of Medicine and Zacharon Pharmaceuticals, have developed a simple, reliable test for identifying biomarkers for mucopolysaccharidoses (MPS), a group of inherited metabolic disorders that are currently diagnosed in patients only after symptoms have become serious and the damage possibly irreversible.

8 Jan 2012

Positive results from BioCryst's BCX4208 Phase 2b study on gout

BioCryst Pharmaceuticals, Inc. announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

8 Jan 2012

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.

7 Jan 2012

Cannabis Science extracts benefit squamous cell carcinoma cancer and skin cancer patients

We stumbled upon this news a couple weeks back regarding Cannabis Science, Inc. reported the continuing successful progress by two patients who have been topically self-administering Cannabis Science extracts for Squamous Cell Carcinoma Cancer and Skin Cancer.

7 Jan 2012

Study shows high consistency of malignancy-risk gene signature on both breast cancer and NSCLC

A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt Cancer Center in Tampa, Fla., who published their study results in a recent issue of the Journal of the National Cancer Institute.

7 Jan 2012

AnaptysBio enters new strategic alliances for antibody discovery

AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company.

7 Jan 2012

Study provides hope for stimulating remyelination in MS patients

Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body's ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.

7 Jan 2012

Age-associated decline of remyelination process may be reversible

New research highlights the possibility of reversing ageing in the central nervous system for multiple sclerosis (MS) patients. The study is published today, 06 January, in the journal Cell Stem Cell.

7 Jan 2012

Poor nutrition in the womb can increase risk of type 2 diabetes in later life

Researchers funded by the Biotechnology and Biological Sciences Research Council have shown one way in which poor nutrition in the womb can put a person at greater risk of developing type 2 diabetes and other age-related diseases in later life.

7 Jan 2012

The Tech Group, Pepex partner to develop Trio systems and sensor modules

Pepex Biomedical, Inc., a privately held company that has developed an all new proprietary sensor technology known as "CCM", announced today it has reached an agreement with The Tech Group , a division of West Pharmaceuticals Services, Inc., to be the premier manufacturer of the Trio systems and sensor modules.

7 Jan 2012

Researchers crack structure and function of malarial protein

A biology lab at Washington University has just cracked the structure and function of a protein that plays a key role in the life of a parasite that killed 655,000 people in 2010.

7 Jan 2012

SPIE to honor CCNY professor with Britton Chance Biomedical Optics Award

A scientific innovator from The City College of New York (CCNY) whose research unites the divergent fields of medicine, biology and high-speed laser physics will be honored this month for his pioneering work in biomedical optics by SPIE, the international society for optics and photonics.

7 Jan 2012

PCI Biotech focuses on localised cancer therapy with minimum side effects

Side effects are currently the biggest problem with any cancer treatment. A Norwegian biotech company is drawing closer to the goal of creating a treatment which kills only cancer cells, leaving other cells unaffected.

7 Jan 2012

VisionGate achieves full automation of Cell-CT system

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer and other applications, today reported that it has achieved full automation of its Cell-CT system, a proprietary imaging platform that generates high-resolution 3D biosignatures from intact cells.

7 Jan 2012

Studies identify genes and small molecules against protein conformational diseases

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes.

7 Jan 2012